Clinical Trial Update: Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on the safety and tolerability assessment of KH658 gene therapy in subjects with neovascular age-related macular degeneration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH658 gene therapy

Snippet

Sponsor: Chengdu Origen Biotechnology Co., Ltd. | Conditions: Age-related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING